Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.55
TPI's Cash to Debt is ranked higher than
78% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TPI: 3.55 )
TPI' s 10-Year Cash to Debt Range
Min: 3.29   Max: No Debt
Current: 3.55

Equity to Asset 0.91
TPI's Equity to Asset is ranked higher than
96% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. TPI: 0.91 )
TPI' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.91
Current: 0.91

-0.16
0.91
Interest Coverage 6.85
TPI's Interest Coverage is ranked higher than
55% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. TPI: 6.85 )
TPI' s 10-Year Interest Coverage Range
Min: 6.85   Max: 9999.99
Current: 6.85

6.85
9999.99
F-Score: 3
Z-Score: 2.71
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.77
TPI's Operating margin (%) is ranked higher than
69% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. TPI: 5.77 )
TPI' s 10-Year Operating margin (%) Range
Min: -628.57   Max: 23.06
Current: 5.77

-628.57
23.06
Net-margin (%) -1.38
TPI's Net-margin (%) is ranked higher than
59% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. TPI: -1.38 )
TPI' s 10-Year Net-margin (%) Range
Min: -628.57   Max: 18.83
Current: -1.38

-628.57
18.83
ROE (%) -0.64
TPI's ROE (%) is ranked higher than
61% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. TPI: -0.64 )
TPI' s 10-Year ROE (%) Range
Min: -108.64   Max: 36.26
Current: -0.64

-108.64
36.26
ROA (%) -0.59
TPI's ROA (%) is ranked higher than
61% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. TPI: -0.59 )
TPI' s 10-Year ROA (%) Range
Min: -44   Max: 32.35
Current: -0.59

-44
32.35
ROC (Joel Greenblatt) (%) 4.84
TPI's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. TPI: 4.84 )
TPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -338.46   Max: 127.19
Current: 4.84

-338.46
127.19
Revenue Growth (3Y)(%) -21.00
TPI's Revenue Growth (3Y)(%) is ranked higher than
53% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TPI: -21.00 )
TPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 457.2
Current: -21

0
457.2
EBITDA Growth (3Y)(%) -51.70
TPI's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TPI: -51.70 )
TPI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 19.1
Current: -51.7

0
19.1
» TPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TPI Guru Trades in Q4 2013

Jim Simons 488,700 sh (+19.05%)
» More
Q1 2014

TPI Guru Trades in Q1 2014

Jim Simons 620,100 sh (+26.89%)
» More
Q2 2014

TPI Guru Trades in Q2 2014

Jim Simons 680,100 sh (+9.68%)
» More
Q3 2014

TPI Guru Trades in Q3 2014

Jim Simons 714,400 sh (+5.04%)
» More
» Details

Insider Trades

Latest Guru Trades with TPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.21
TPI's P/B is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. TPI: 0.21 )
TPI' s 10-Year P/B Range
Min: 0.14   Max: 2.76
Current: 0.21

0.14
2.76
P/S 0.45
TPI's P/S is ranked higher than
98% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. TPI: 0.45 )
TPI' s 10-Year P/S Range
Min: 0.19   Max: 3.54
Current: 0.45

0.19
3.54
EV-to-EBIT 3.35
TPI's EV-to-EBIT is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. TPI: 3.35 )
TPI' s 10-Year EV-to-EBIT Range
Min: -1.9   Max: 19.3
Current: 3.35

-1.9
19.3
Shiller P/E 2.30
TPI's Shiller P/E is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 165.76 vs. TPI: 2.30 )
TPI' s 10-Year Shiller P/E Range
Min: 1.49   Max: 3.35
Current: 2.3

1.49
3.35
Current Ratio 3.68
TPI's Current Ratio is ranked higher than
81% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. TPI: 3.68 )
TPI' s 10-Year Current Ratio Range
Min: 0.11   Max: 5.39
Current: 3.68

0.11
5.39
Quick Ratio 3.26
TPI's Quick Ratio is ranked higher than
82% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TPI: 3.26 )
TPI' s 10-Year Quick Ratio Range
Min: 0.11   Max: 4.81
Current: 3.26

0.11
4.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.92
TPI's Price/Net Cash is ranked higher than
98% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TPI: 2.92 )
TPI' s 10-Year Price/Net Cash Range
Min: 0.72   Max: 6.52
Current: 2.92

0.72
6.52
Price/Net Current Asset Value 1.32
TPI's Price/Net Current Asset Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TPI: 1.32 )
TPI' s 10-Year Price/Net Current Asset Value Range
Min: 0.46   Max: 3.99
Current: 1.32

0.46
3.99
Price/Tangible Book 0.30
TPI's Price/Tangible Book is ranked higher than
100% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. TPI: 0.30 )
TPI' s 10-Year Price/Tangible Book Range
Min: 0.19   Max: 2.33
Current: 0.3

0.19
2.33
Price/DCF (Projected) 0.31
TPI's Price/DCF (Projected) is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. TPI: 0.31 )
TPI' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 0.31
Current: 0.31

0.16
0.31
Price/Median PS Value 0.89
TPI's Price/Median PS Value is ranked higher than
94% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TPI: 0.89 )
TPI' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 4.1
Current: 0.89

0.41
4.1
Earnings Yield (Greenblatt) 29.90
TPI's Earnings Yield (Greenblatt) is ranked higher than
99% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TPI: 29.90 )
TPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 6688.7
Current: 29.9

5.2
6688.7
Forward Rate of Return (Yacktman) -24.13
TPI's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. TPI: -24.13 )
TPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -28.3   Max: 31.4
Current: -24.13

-28.3
31.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:60T.Germany,
Tianyin Pharmaceutical Co, Inc., previously called Viscorp, Inc., was originally formed as a limited liability company under the laws of the State of Delaware on August 20, 2002. The Company is engaged in the development, manufacturing, marketing and sales of patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and other pharmaceuticals in China. The Company currently manufactures a portfolio of 58 products, 24 of which are listed in the highly selective National Medical Reimbursement List and 10 are listed in the National Essential Drug List of China. It sells its products via regional distributors as well as directly to the hospitals, clinics, and pharmacies in China. Its geographical location at Sichuan province facilitates an access to high-grade raw ingredients for both raw materials for chemical medicine as well as Chinese medicines. The traditional Chinese medicine (TCM) industry in China is highly fragmented and intensely competitive. It faces competition from domestic TCM manufacturers, as well as domestic and foreign pharmaceuticals providers with similar therapeutic effects. China's pharmaceutical industry is highly regulated by the government. The primary regulatory authority is the CFDA, including its provincial and local branches, by which it is subject to regulation and oversight. China's healthcare laws stipulate the production and sale of pharmaceuticals in China, covering the manufacturing, distributing, packaging, pricing and advertising of pharmaceutical products. It is also subject to other Chinese laws and regulations that are applicable to business operators, manufacturers and distributors in general.
» More Articles for TPI

Headlines

Articles On GuruFocus.com
5 year low Apr 21 2013 
8 Healthcare Dividend Stocks Close To 52-Week Low Sep 03 2011 
18 Low Beta Healthcare Stocks With Best Dividend Yields Jul 02 2011 
High Yields In Healthcare Sector May 26 2011 
Tianyin Pharmaceutical Co., Inc. Receives Production License to Launch Tongbianling Capsules Dec 22 2008 

More From Other Websites
8:02 am Tianyin Pharma announced that the Company is engaged in discussion with a pharmaceutical... Dec 26 2014
TPI in Talks with Well Capitalized Strategic Partner to Form Alliance to Build Nationwide Platform Dec 26 2014
TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results Dec 24 2014
TPI QLF Achieved Public Notice Status of GMP Certification Dec 23 2014
TPI New Qionglai Facility (QLF) Updates Dec 18 2014
TPI Expects Receiving GMP by the end of December 2014 Dec 16 2014
TPI in Talk with Industrial Leaders on Alliance to Boost Revenue for 2015 Dec 15 2014
TIANYIN PHARMACEUTICAL CO., INC. Financials Dec 13 2014
TPI Reports Fiscal Year 2014 Financial Results Dec 10 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 10-K, Annual Report Dec 09 2014
TPI Updates on its New Facility GMP Certification Progress and Growth Strategies Dec 02 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Oct 27 2014
TPI's QLF Updates on its GMP Certification Progress Oct 23 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Oct 21 2014
Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Oct 21 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 16 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Oct 15 2014
Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Oct 15 2014
TPI's QLF Completes GMP site inspection by CFDA Sep 29 2014
JCM Applies for Azithromycin API Import Certificate at India Sep 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK